BioXcel Therapeutics
BTAI
94 hedge funds and large institutions have $167M invested in BioXcel Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 16 closing their positions.
26% more call options, than puts
Call options by funds: $2.11M | Put options by funds: $1.68M
14% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 28
0.09% less ownership
Funds ownership: 2.93% → 2.83% (-0.09%)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
2% less funds holding
Funds holding: 96 → 94 (-2)
39% less capital invested
Capital invested by funds: $274M → $167M (-$106M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.22M |
| 2 |
BlackRock
New York
|
+$1.87M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$1.62M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$1.34M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13.6M |
| 2 |
Rafferty Asset Management
New York
|
-$1.94M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.69M |
| 4 |
Jane Street
New York
|
-$1.63M |
| 5 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$897K |
BTAI Hedge Fund Activity: Q2 2022 in Review
94 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2022, worth a combined $167M — down 39% from $274M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of BTAI and 15 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 32 added.
The largest buyer was Millennium Management, adding an estimated $2.22M. The largest seller was State Street, cutting an estimated $13.6M.
- 94 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2022, down from 96 in Q1 2022.
- Funds reported $167M of BioXcel Therapeutics stock for Q2 2022, down 39% quarter-over-quarter.
- 15 funds opened new BioXcel Therapeutics positions in Q2 2022 and 16 closed out, a net change of -1 holder.
- The largest BioXcel Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $2.22M added.
- The largest BioXcel Therapeutics seller in Q2 2022 was State Street, an estimated $13.6M sold.
Based on aggregated 13F filings for Q2 2022.